Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 ...
Vera Therapeutics completed early enrollment for ORIGIN 3 trial of atacicept in IgAN, with 200 participants for 36-week UPCR primary endpoint. Topline results expected Q2 2025, and 96-week data from ORIGIN Phase 2b trial to be presented Q4 2024.
Related Clinical Trials
Reference News
Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 ...
Vera Therapeutics completed early enrollment for ORIGIN 3 trial of atacicept in IgAN, with 200 participants for 36-week UPCR primary endpoint. Topline results expected Q2 2025, and 96-week data from ORIGIN Phase 2b trial to be presented Q4 2024.